CA2506128A1 - Anti-activated ras antibodies - Google Patents

Anti-activated ras antibodies Download PDF

Info

Publication number
CA2506128A1
CA2506128A1 CA002506128A CA2506128A CA2506128A1 CA 2506128 A1 CA2506128 A1 CA 2506128A1 CA 002506128 A CA002506128 A CA 002506128A CA 2506128 A CA2506128 A CA 2506128A CA 2506128 A1 CA2506128 A1 CA 2506128A1
Authority
CA
Canada
Prior art keywords
seq
antibody
scfv
ras
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002506128A
Other languages
English (en)
French (fr)
Inventor
Terence Howard Rabbitts
Tomoyuki Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0226728A external-priority patent/GB0226728D0/en
Priority claimed from GB0226731A external-priority patent/GB0226731D0/en
Priority claimed from GB0226723A external-priority patent/GB0226723D0/en
Priority claimed from GBGB0226729.2A external-priority patent/GB0226729D0/en
Priority claimed from GBGB0226727.6A external-priority patent/GB0226727D0/en
Priority claimed from GB0316680A external-priority patent/GB0316680D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of CA2506128A1 publication Critical patent/CA2506128A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002506128A 2002-11-15 2003-11-14 Anti-activated ras antibodies Abandoned CA2506128A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0226728.4 2002-11-15
GB0226728A GB0226728D0 (en) 2002-11-15 2002-11-15 Anti-activated RAS antibodies
GB0226731A GB0226731D0 (en) 2002-11-15 2002-11-15 Method for generating immunoglobulin genes
GB0226723A GB0226723D0 (en) 2002-11-15 2002-11-15 Antibodies for in vitro use
GBGB0226729.2A GB0226729D0 (en) 2002-11-15 2002-11-15 Intracellular antibodies
GBGB0226727.6A GB0226727D0 (en) 2002-11-15 2002-11-15 Intrabodies
GB0226723.5 2002-11-15
GB0226727.6 2002-11-15
GB0226731.8 2002-11-15
GB0226729.2 2002-11-15
GB0316680.8 2003-07-16
GB0316680A GB0316680D0 (en) 2003-07-16 2003-07-16 Anti-activated RAS antibodies
PCT/GB2003/004953 WO2004046188A2 (en) 2002-11-15 2003-11-14 Anti-activated ras antibodies

Publications (1)

Publication Number Publication Date
CA2506128A1 true CA2506128A1 (en) 2004-06-03

Family

ID=32330172

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002506128A Abandoned CA2506128A1 (en) 2002-11-15 2003-11-14 Anti-activated ras antibodies

Country Status (6)

Country Link
US (1) US20050288492A1 (https=)
EP (1) EP1565495A2 (https=)
JP (1) JP2006521088A (https=)
AU (1) AU2003282247A1 (https=)
CA (1) CA2506128A1 (https=)
WO (1) WO2004046188A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336323A3 (en) * 2005-03-25 2012-05-23 National Research Council Of Canada Method for isolation of soluble polypeptides
EP1867661A1 (en) * 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
CN106357366B (zh) 2008-03-12 2020-04-10 松下电器（美国）知识产权公司 通信装置以及通信方法
AU2010238346A1 (en) * 2009-04-14 2011-11-03 Trojan Technologies Ltd. Therapeutic Antennapedia-antibody molecules and methods of use thereof
GB201103631D0 (en) * 2011-03-03 2011-04-13 Univ Leeds Identification of candidate therapeutics
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
KR101602876B1 (ko) * 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
WO2016013871A1 (ko) * 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
IL313511A (en) 2014-11-12 2024-08-01 Seagen Inc Compounds acting on glycans and methods of using them
EP3373969A4 (en) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
MX2018014554A (es) 2016-05-27 2019-09-09 Orum Therapeutics Inc Anticuerpo penetrante de citosol y uso del mismo.
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
CN118240025A (zh) 2017-07-10 2024-06-25 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
US11965004B2 (en) 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof
KR20190143826A (ko) 2018-06-21 2019-12-31 오름테라퓨틱 주식회사 세포/조직 특이적 세포 침투 항체
GB202006974D0 (en) * 2020-05-12 2020-06-24 Univ Oxford Innovation Ltd Chimaeric proteins and therapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219277A1 (en) * 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies

Also Published As

Publication number Publication date
EP1565495A2 (en) 2005-08-24
WO2004046188A3 (en) 2004-09-16
US20050288492A1 (en) 2005-12-29
WO2004046188A2 (en) 2004-06-03
JP2006521088A (ja) 2006-09-21
AU2003282247A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
US20050288492A1 (en) Anti-activated RAS antibodies
US20050276800A1 (en) Intrabodies
ES2052027T5 (es) Clonacion de secuencias de dominio variable de inmunoglobulina.
CN108884160B (zh) 抗ror1抗体
DK2675826T3 (en) Antibody to CSF-1R
JP7663977B2 (ja) 抗ｐｄ―ｌ１抗体およびその用途
US20100143939A1 (en) Intracellular antibodies
WO2003077945A1 (en) Intracellular antibodies
US11390686B2 (en) HER3 binding agents and uses thereof
WO2003105782A2 (en) Specificity grafting of a murine antibody onto a human framework
JP2010260845A (ja) Ｍｎ結合および細胞接着中和活性を有するヒト抗体
JP2004500828A (ja) Ｍｕｃｉｎ−１特異的結合メンバー及びその使用方法
AU2018290898B2 (en) Chimeric antibodies for treatment of amyloid deposition diseases
US20250197481A1 (en) Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
CN113004416B (zh) 靶向her2-cd137双特异性抗体的构建及其应用
WO2004046187A2 (en) Antibodies for in vitro use
WO2024173565A2 (en) Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants
Little et al. Recombinant Antibodies: Construction and Production
Olsen Functional investigation of the EWS/ATF1 fusion protein: Implications for molecular therapy in clear cell sarcoma
Schellekens Molecular aspects of antibody-antigen interactions: size reduction of a herpes simplex virus neutralizing antibody and its antigen
Marshall Towards cancer immunotherapy: Analysis of a tumor targeting antibody and engineering of a novel fusion protein to activate cytotoxic T cells
CN103374071A (zh) 一种抗derlin-1人源化抗体的制备

Legal Events

Date Code Title Description
FZDE Discontinued